A detailed history of New Edge Advisors, LLC transactions in Argenx Se stock. As of the latest transaction made, New Edge Advisors, LLC holds 988 shares of ARGX stock, worth $424,879. This represents 0.0% of its overall portfolio holdings.

Number of Shares
988
Previous 1,100 10.18%
Holding current value
$424,879
Previous $418,000 7.18%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$356.95 - $413.29 $39,978 - $46,288
-112 Reduced 10.18%
988 $388,000
Q4 2023

Feb 13, 2024

BUY
$338.91 - $506.01 $235,542 - $351,676
695 Added 171.6%
1,100 $418,000
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $40,628 - $60,327
110 Added 37.29%
405 $199,000
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $2,160 - $2,535
6 Added 2.08%
295 $114,000
Q1 2023

May 12, 2023

SELL
$334.23 - $403.65 $5,681 - $6,862
-17 Reduced 5.56%
289 $107,000
Q4 2022

Feb 14, 2023

BUY
$342.17 - $402.31 $104,704 - $123,106
306 New
306 $115,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $23.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.